If its renoprotective mechanism is clarified at the theoretical level, it will help to explore whether SGLT2 inhibition can be used as novel renoprotective drugs to stop or slow down the progression of chronic kidney disease and to promote clinical application in patients with non-diabetic nephropathy. The gene discussed is SLC5A2; the disease is chronic kidney disease.